Does Adjuvant Therapy Affect Quality of Life in Resected Melanoma Patients?
Source: Cancer Network, May 2019
There was no difference in health-related quality of life among patients with resected stage III melanoma with BRAF mutations treated with adjuvant dabrafenib plus trametinib and those assigned to placebo, according to a patient-reported outcomes analysis of the COMBI-AD study.
“Our findings provide evidence that adjuvant dabrafenib plus trametinib did not have any substantial effect on patient health-related quality of life,” wrote Dirk Schadendorf, MD, of University Hospital Essen in Germany, and colleagues, in Lancet Oncology. “Furthermore, there was a substantial decrease in health-related quality of life after disease recurrence, highlighting the benefit to patients of remaining relapse-free and supporting the use of dabrafenib plus trametinib on the basis of a significant improvement in relapse-free survival in the primary analysis.”
The phase III COMBI-AD study found that combination adjuvant treatment with dabrafenib plus trametinib significantly improved relapse-free survival at 3 years in patients with resected stage III melanoma with BRAF V600E or BRAF V600K mutations.